AOA Dx

AOA Dx tackled ovarian cancer's most devastating reality: most cases go undetected until advanced stages when survival rates plummet. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌Women with early-stage disease face a 90% five-year survival rate, but this drops dramatically once cancer spreads—yet roughly 70% of patients present with late-stage tumors. Gynecologists and oncologists experienced this acutely, lacking reliable screening tools beyond imaging and CA-125 blood markers, which miss many early cases and generate false positives. The problem was measurable: ovarian cancer kills more women than any other gynecologic malignancy, with survival rates stagnating for decades. Existing alternatives—transvaginal ultrasound and CA-125 testing—proved inadequate for asymptomatic screening. Early validation came through partnerships with major cancer centers and positive preliminary data showing their glycolipid biomarkers could detect early-stage disease with superior sensitivity and specificity compared to standard markers. Physician interest and patient demand for better screening options validated that the market urgently needed their approach.